Claims for Patent: 8,268,847

Summary for Patent: 8,268,847

Title:	Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor
Abstract:	The invention relates to a product containing the compound of formula (I) below ##STR00001## or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having PDE5-inhibitory properties, or a pharmaceutically acceptable salt thereof, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved.
Inventor(s):	Clozel; Martine (Binningen, CH)
Assignee:	Actelion Pharmaceuticals, Ltd. (Allschwil, CH)
Application Number:	12/439,290
Patent Claims:	1. A product containing the compound of formula (I) below ##STR00006## in free or pharmaceutically acceptable salt form, in combination with at least one compound having PDE5-inhibitory properties, in free or a pharmaceutically acceptable salt form, for therapeutic use, simultaneously, separately or over a period of time, in the treatment of a disease wherein vasoconstriction is involved. 2. The product according to claim 1, wherein the compound having PDE5-inhibitory properties is selected from sildenafil, vardenafil, tadalafil and udenafil. 3. The product according to claim 2, wherein the compound having PDE5-inhibitory properties is tadalafil. 4. The product according to claim 2, wherein the compound having PDE5-inhibitory properties is sildenafil. 5. The product according to claim 1, wherein the disease wherein vasoconstriction is involved is selected from hypertension, pulmonary hypertension, diabetic arteriopathy, heart failure, erectile dysfunction and angina pectoris. 6. A pharmaceutical composition containing, as active principles, the compound of formula (I) as described in claim 1, in free or pharmaceutically acceptable salt form, in combination with at least one compound having PDE5-inhibitory properties, in free or pharmaceutically acceptable salt form, as well as at least one excipient. 7. The pharmaceutical composition according to claim 6, wherein the compound having PDE5-inhibitory properties is selected from sildenafil, vardenafil, tadalafil and udenafil. 8. The pharmaceutical composition according to claim 7, wherein the compound having PDE5-inhibitory properties is tadalafil. 9. The pharmaceutical composition according to claim 7, wherein the compound having PDE5-inhibitory properties is sildenafil. 10. A method for the treatment of hypertension or pulmonary hypertension comprising administering to a patient in need thereof an effective amount of a compound of formula (I) as described in claim 1, in free or pharmaceutically acceptable salt form, in combination with at least one compound having PDE5-inhibitory properties, in free or pharmaceutically acceptable salt form. 11. The method according to claim 10, wherein the compound having PDE5-inhibitory properties is selected from sildenafil, vardenafil, tadalafil and udenafil.